Therefore, the TFF1 and TFF3 biomarkers may provide healthcare professionals with tools to better subclassify OC by histotype, more efficiently predict patient clinical outcome, and improve the treatment decision-making process for ovarian cancer. This evidence concerns the gene TFF1 and ovarian carcinoma.